Skip to main content

Wave Life Sciences Ltd. (WVE)

NASDAQ: WVE · IEX Real-Time Price · USD
5.20
+0.05 (0.97%)
After-hours:Oct 15, 2021 6:41 PM EDT
5.15
0.43 (9.11%)
At close: Oct 15, 4:00 PM
Market Cap261.47M
Revenue (ttm)15.67M
Net Income (ttm)-143.12M
Shares Out50.77M
EPS (ttm)-3.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume525,980
Open4.82
Previous Close4.72
Day's Range4.74 - 5.22
52-Week Range4.48 - 12.17
Beta0.55
AnalystsBuy
Price Target9.86 (+91.5%)
Est. Earnings DateNov 8, 2021

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials f...

IndustryPharmaceuticals
IPO DateNov 11, 2015
CEOPaul Bolno
Employees217
Stock ExchangeNASDAQ
Ticker SymbolWVE
Full Company Profile

Financial Performance

In 2020, WVE's revenue was $20.08 million, an increase of 25.61% compared to the previous year's $15.98 million. Losses were -$149.91 million, -22.58% less than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 9.86, which is an increase of 91.46% from the latest price.

Price Target
$9.86
(91.46% upside)
Analyst Consensus: Buy

News

Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies

Wave Life Sciences Ltd (NASDAQ: WVE) presented new preclinical data for its ADAR-mediated RNA editing capability (ADAR editing) and an update on its discovery-stage alpha-1 antitrypsin deficiency (AATD)...

2 weeks ago - Benzinga

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update ...

Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months

2 weeks ago - GlobeNewsWire

Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...

3 weeks ago - GlobeNewsWire

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor R...

Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT

1 month ago - GlobeNewsWire

Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...

1 month ago - GlobeNewsWire

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -27.87% and -76.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study

2 months ago - GlobeNewsWire

Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021

CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

2 months ago - GlobeNewsWire

Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study

Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin defic...

4 months ago - Benzinga

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Defici...

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency

4 months ago - GlobeNewsWire

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

4 months ago - GlobeNewsWire

Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: WAVE Life Sciences Q1 Earnings

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimate ...

5 months ago - Benzinga

Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

Clinical trials underway with next-generation candidates incorporating PN chemistry

5 months ago - GlobeNewsWire

Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

5 months ago - GlobeNewsWire

Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

5 months ago - GlobeNewsWire

5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:AFMDCMRXEPZMSEEL
6 months ago - 24/7 Wall Street

Here's Why Wave Life Sciences Crashed Today

No one ever said drug development was easy.

6 months ago - The Motley Fool

Wave Life Sciences Stock Plunges After Antisense Oligonucleotide Candidates Disappoint In Huntington's Disease Study

Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happ...

6 months ago - Benzinga

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101

6 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...

6 months ago - GlobeNewsWire

Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

WAVE Life Sciences: Q4 Earnings Insights

Shares of WAVE Life Sciences (NASDAQ:WVE) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 64.24% year over year to ($0.59), which beat the estimat...

7 months ago - Benzinga